Royal Bank of Canada’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-35,403
| Closed | -$5K | – | 7737 |
|
|
2024
Q1 | $5K | Sell |
35,403
-421
| -1% | -$83 | ﹤0.01% | 6472 |
|
|
2023
Q4 | $5K | Buy |
35,824
+732
| +2% | +$114 | ﹤0.01% | 6665 |
|
|
2023
Q3 | $6K | Buy |
35,092
+13,149
| +60% | +$16.3K | ﹤0.01% | 6591 |
|
|
2023
Q2 | $68K | Buy |
21,943
+12,055
| +122% | +$35.9K | ﹤0.01% | 5615 |
|
|
2023
Q1 | $26K | Buy |
9,888
+2,188
| +28% | +$4.51K | ﹤0.01% | 5932 |
|
|
2022
Q4 | $11K | Sell |
7,700
-1,804
| -19% | -$2.93K | ﹤0.01% | 6527 |
|
|
2022
Q3 | $16K | Buy |
9,504
+294
| +3% | +$416 | ﹤0.01% | 6241 |
|
|
2022
Q2 | $12K | Sell |
9,210
-43
| -0.5% | -$74 | ﹤0.01% | 6328 |
|
|
2022
Q1 | $22K | Sell |
9,253
-622
| -6% | -$1.62K | ﹤0.01% | 6560 |
|
|
2021
Q4 | $45K | Buy |
9,875
+2,175
| +28% | +$7.19K | ﹤0.01% | 6435 |
|
|
2021
Q3 | $62K | Buy |
7,700
+7,416
| +2,611% | +$63.6K | ﹤0.01% | 6034 |
|
|
2021
Q2 | $3K | Sell |
284
-476
| -63% | -$3.87K | ﹤0.01% | 7201 |
|
|
2021
Q1 | $7K | Buy |
760
+312
| +70% | +$3.43K | ﹤0.01% | 6963 |
|
|
2020
Q4 | $5K | Buy |
+448
| New | +$4.9K | ﹤0.01% | 6673 |
|
|
2020
Q3 | – | Sell |
-6
| Closed | – | – | 7028 |
|
|
2020
Q2 | $0 | Sell |
6
-692
| -99% | -$7.35K | ﹤0.01% | 6990 |
|
|
2020
Q1 | $7K | Buy |
698
+597
| +591% | +$7.69K | ﹤0.01% | 5954 |
|
|
2019
Q4 | $1K | Buy |
+101
| New | +$1.23K | ﹤0.01% | 6710 |
|
Other funds holding GRTX
Royal Bank of Canada's GRTX Position: Q2 2024 in Review
Royal Bank of Canada sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2024, closing a stake of 35,403 shares — an estimated $5K sold.
Royal Bank of Canada first reported a position in GRTX in Q4 2019 and held it in 17 quarters. The position peaked at $68K in Q2 2023. 1 fund tracked by Wall St. Rank holds GRTX as of Q2 2024.
- Royal Bank of Canada reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Royal Bank of Canada sold 35,403 Galera Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $5K.
- Royal Bank of Canada first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
- Royal Bank of Canada's Galera Therapeutics, Inc. Common Stock position peaked at $68K in Q2 2023.
- 1 fund tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2024.
Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.